Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Study assesses impact of UV1 in ovarian cancer maintenance careAddresses unmet medical need among BRCA-negative ovarian cancer patients Enrollment of 184 patients to be coordinated through NSGO-CTU...
-
Designation covers UV1 in Metastatic Melanoma as sole agent or part of combinationSeven-year market exclusivity after regulatory approval, if received Oslo, 2 December 2021: Ultimovacs ASA...
-
Oslo, 2 December 2021, Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,000 shares in the company at a price of NOK 107.60 per share. Following this...
-
Oslo, 29 November 2021, Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,000 shares in the company at a price of NOK 114.00 per share, and a closely...
-
Oslo, Norway, November 25, 2021: Radforsk Investeringsstiftelse, a legal person closely associated with a person discharging managerial responsibilities in Ultimovacs ASA has notified the company of a...
-
Oslo, 11 November 2021: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its third quarter 2021 results today. The presentation by...
-
UV1 vaccine combined with ipilimumab induced immune responses in 91% of melanoma patientsImmune responses persist and are detectable up to 5 years Oslo, November 9, 2021: Ultimovacs ASA...
-
Oslo, 3 November 2021: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, invites to a webcast presentation of its third quarter 2021 results...
-
Oslo, Norway, 2 November 2021 Reference is made to the stock exchange announcement published by Ultimovacs ASA (the "Company") on 27 October 2021 regarding the successful placing of a private...
-
Reference is made to the stock exchange announcement by Ultimovacs ASA (OSE: ULTI) ("Ultimovacs” or the "Company") on 26 October 2021 regarding the successful placing of a private placement of new...